WO2002072009A3 - Heterocyclic derivatives for the treatment of cancer and other proliferative diseases - Google Patents

Heterocyclic derivatives for the treatment of cancer and other proliferative diseases Download PDF

Info

Publication number
WO2002072009A3
WO2002072009A3 PCT/US2002/007001 US0207001W WO02072009A3 WO 2002072009 A3 WO2002072009 A3 WO 2002072009A3 US 0207001 W US0207001 W US 0207001W WO 02072009 A3 WO02072009 A3 WO 02072009A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
aryl
heteroaryl
cancer
treatment
Prior art date
Application number
PCT/US2002/007001
Other languages
French (fr)
Other versions
WO2002072009A2 (en
Inventor
Magnus Pfahl
Hussein A Al-Shamma
Andrea Fanjul
David P M Pleynet
Lyle W Spruce
Torsten R Wiemann
Jason B Ibarra
Catherine Tachdjian
Original Assignee
Maxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxia Pharmaceuticals Inc filed Critical Maxia Pharmaceuticals Inc
Priority to EP02721289A priority Critical patent/EP1385465A4/en
Priority to MXPA03008117A priority patent/MXPA03008117A/en
Priority to CA002440184A priority patent/CA2440184A1/en
Priority to IL15774002A priority patent/IL157740A0/en
Priority to EA200300982A priority patent/EA200300982A1/en
Priority to BR0207846-5A priority patent/BR0207846A/en
Priority to JP2002570969A priority patent/JP2005506290A/en
Priority to AU2002252227A priority patent/AU2002252227A1/en
Publication of WO2002072009A2 publication Critical patent/WO2002072009A2/en
Priority to NO20033883A priority patent/NO20033883L/en
Publication of WO2002072009A3 publication Critical patent/WO2002072009A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the formula (1): wherein (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) ----- represents a bond present or absent; and (g) W, X, Y and Z are independently or together -C(O)-,C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.
PCT/US2002/007001 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases WO2002072009A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP02721289A EP1385465A4 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
MXPA03008117A MXPA03008117A (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases.
CA002440184A CA2440184A1 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
IL15774002A IL157740A0 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives and pharmaceutical compositions containing the same
EA200300982A EA200300982A1 (en) 2001-03-07 2002-03-07 HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES
BR0207846-5A BR0207846A (en) 2001-03-07 2002-03-07 Heterocyclic Derivatives for the Treatment of Cancer and Other Proliferative Diseases
JP2002570969A JP2005506290A (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for treating cancer and other proliferative diseases
AU2002252227A AU2002252227A1 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
NO20033883A NO20033883L (en) 2001-03-07 2003-09-02 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27475101P 2001-03-07 2001-03-07
US60/274,751 2001-03-07

Publications (2)

Publication Number Publication Date
WO2002072009A2 WO2002072009A2 (en) 2002-09-19
WO2002072009A3 true WO2002072009A3 (en) 2003-10-16

Family

ID=23049469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007001 WO2002072009A2 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

Country Status (12)

Country Link
US (1) US7153875B2 (en)
EP (1) EP1385465A4 (en)
JP (1) JP2005506290A (en)
AU (1) AU2002252227A1 (en)
BR (1) BR0207846A (en)
CA (1) CA2440184A1 (en)
EA (1) EA200300982A1 (en)
IL (1) IL157740A0 (en)
MX (1) MXPA03008117A (en)
NO (1) NO20033883L (en)
PL (1) PL373912A1 (en)
WO (1) WO2002072009A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002257A (en) 1999-08-31 2002-09-30 Maxia Pharmaceuticals Inc Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes.
CA2440184A1 (en) 2001-03-07 2002-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
EP1377559A4 (en) 2001-03-08 2005-09-28 Incyte San Diego Inc Rxr activating molecules
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
JP2005513026A (en) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases
US7053071B2 (en) 2001-11-30 2006-05-30 The Burnham Institute Induction of apoptosis in cancer cells
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
FR2856401B1 (en) * 2003-06-20 2010-02-12 Galderma Res & Dev NOVEL MODULATING COMPOUNDS OF PPARGAMMA RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
DE10351744A1 (en) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinones, their preparation and use as pharmaceuticals
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
EP2210869A1 (en) 2005-04-08 2010-07-28 Galderma Research & Development New method for the preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
FR2884248B1 (en) * 2005-04-08 2007-05-18 Galderma Res & Dev NOVEL PROCESS FOR THE PREPARATION OF 6- [3- (1-ADAMANTYL) -4-METHOXYPHENYL] -2-NAPHTHOIC ACID
KR100814109B1 (en) 2006-01-09 2008-03-14 한국생명공학연구원 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same
TW200815429A (en) * 2006-04-11 2008-04-01 Smithkline Beecham Corp Thiazolidinedione derivatives as PI3 kinase inhibitors
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
PE20090288A1 (en) * 2007-05-10 2009-04-03 Smithkline Beecham Corp QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
PE20090717A1 (en) * 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
EP2674417A3 (en) 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
CN102558088A (en) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 Biphenyl methylene-2-sulpho-4-thiazolone compound as well as preparation method and application thereof
WO2023121184A1 (en) * 2021-12-21 2023-06-29 (주)메디픽 Substituted thiazolidinedione derivative compound, and pharmaceutical composition for preventing or treating cancer, comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (en) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantable dosing device
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
EP0304493B1 (en) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
FI91869C (en) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Process for the preparation of benzoxazole derivatives as antidiabetic agents
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
WO1993002060A1 (en) 1991-07-22 1993-02-04 Pfizer, Inc. Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives
EP0983991B1 (en) 1992-04-22 2003-12-17 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
EP0671005A1 (en) 1992-11-25 1995-09-13 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
NZ279689A (en) 1994-02-17 1997-08-22 American Home Prod Substituted biphenyl derivatives, preparation and pharmaceutical compositions thereof
JPH09136877A (en) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd Heterocyclic compound, its production and use thereof
EP0850067A4 (en) 1995-07-17 1999-12-15 Cird Galderma Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl]
CN1196730A (en) 1996-06-19 1998-10-21 雷迪博士研究基金会 Novel polymorphic forms of troglitazone having enhanced anti-brabetic activity and process for their preparation
CN1279902C (en) 1996-07-08 2006-10-18 盖尔德马研究及发展公司 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
CA2300813A1 (en) 1997-08-21 1999-03-04 Hiroyuki Odaka Anti-inflammatory agent
WO1999024415A1 (en) 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Retinoid receptor agonists
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
KR20010099623A (en) 1998-08-21 2001-11-09 비로파마 인코포레이티드 Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
MXPA02002257A (en) * 1999-08-31 2002-09-30 Maxia Pharmaceuticals Inc Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes.
ATE345332T1 (en) 1999-11-12 2006-12-15 Fujimoto Brothers Co Ltd 2-(N-CYANIMINO)THIAZOLIDINE-4-ONE DERIVATIVES
FR2812876B1 (en) 2000-08-08 2002-09-27 Galderma Res & Dev NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
CA2440184A1 (en) 2001-03-07 2002-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
EP1377559A4 (en) 2001-03-08 2005-09-28 Incyte San Diego Inc Rxr activating molecules
DE60204674T2 (en) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis RETINOID X RECEPTOR MODULATORS
EP1392326B1 (en) 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
JP2005513026A (en) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CA2529154C (en) * 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Also Published As

Publication number Publication date
IL157740A0 (en) 2004-03-28
NO20033883L (en) 2003-11-05
PL373912A1 (en) 2005-09-19
EP1385465A4 (en) 2005-09-07
AU2002252227A1 (en) 2002-09-24
JP2005506290A (en) 2005-03-03
US7153875B2 (en) 2006-12-26
US20020143182A1 (en) 2002-10-03
EP1385465A2 (en) 2004-02-04
BR0207846A (en) 2005-09-13
CA2440184A1 (en) 2002-09-19
WO2002072009A2 (en) 2002-09-19
NO20033883D0 (en) 2003-09-02
MXPA03008117A (en) 2004-11-12
EA200300982A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
WO2002072009A3 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
BE2018C008I2 (en)
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
BG106340A (en) Substituted oxoazaheterocyclyl compounds
AU8345491A (en) Heterocyclic derivatives
TW200640900A (en) 1-(2h)-isoquinolone derivative
PL1635835T3 (en) 2-aminopyrimidine derivatives as raf kinase inhibitors
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
MY138263A (en) Therapeutic chroman compounds
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
AU4023093A (en) Novel substituted tertiary amino compound or salt thereof
MY138826A (en) 2,7-substituted indoles
AU2001274806A1 (en) Sulfonamide derivatives
WO2002079753A3 (en) 2-aminobenzoxazole derivatives and combinatorial libraries thereof
UA66866C2 (en) Synthesis of mopholine derivatives
SI1102765T1 (en) PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
GB0215392D0 (en) Chemical compounds
MY129094A (en) Condensed polycyclic compounds
AU2002214320A1 (en) Imidazole derivatives, process for their preparation and their use
MXPA04005151A (en) Therapeutic compounds.
WO2003076426A3 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
WO2002008227A3 (en) Bicyclic hydantoin derivatives and combinatorial libraries thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 157740

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 373912

Country of ref document: PL

Ref document number: 2002570969

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008117

Country of ref document: MX

Ref document number: 028062132

Country of ref document: CN

Ref document number: 2440184

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 528641

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200300982

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002721289

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002721289

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0207846

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2002721289

Country of ref document: EP